Everlywell Takes Breast Cancer AI Risk Tool to Patients — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Everlywell last week launched an AI-based breast cancer risk prediction algorithm aimed directly at patients, bypassing the traditional physician-gated diagnostic process, per STAT.
- Everlywell has sold at-home lab tests — including blood glucose and celiac disease screenings — directly to consumers for a decade, with the call to action "Don't wait. Choose to be informed." on its website.
- Per STAT, the new product fits into "a new generation of AI-based risk prediction algorithms for medical images" now reaching the consumer market.
- The launch falls within STAT's "Paying for AI" series, which examines how clinical AI tools influence healthcare affordability and patients' long-term health outcomes.
Why it matters: By moving breast cancer risk scoring out of specialist clinics and onto Everlywell's existing direct-to-consumer platform, the company sidesteps the clinical gatekeeping that has historically shaped AI imaging diagnostics — a shift the STAT 'Paying for AI' series frames through patient affordability and oversight questions.
Ask SkimNews
